Augustine Therapeutics has reeled in €77.7 million (about $85 million) to take on Charcot-Marie-Tooth disease, neurodegenerative conditions and cardiometabolic disorders.
Two of Europe's leading biotech investment firms — Novo Holdings and Jeito Capital — co-led the Series ...
↧